[AMRN] Amarin Corporation plc

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 3.11 Change: 0.12 (4.01%)
Ext. hours: Change: 0 (0%)

chart AMRN

Refresh chart

Strongest Trends Summary For AMRN

AMRN is in the long-term up 423% in 1 year and up 790% in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases in the United States. It develops products in the areas of lipid science and therapeutic benefits of polyunsaturated fatty acids. The company markets Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. It is also developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-0.33 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 26.39% Sales Growth - Q/Q-3.32% P/E-8.88
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-28.56% ROE99.49% ROI-38.89%
Current Ratio4.46 Quick Ratio4.08 Long Term Debt/Equity1.49 Debt Ratio-0.69
Gross Margin63.04% Operating Margin-164.67% Net Profit Margin-103.96% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities54.3 M Cash From Investing Activities Cash From Operating Activities-12.64 M Gross Profit10.31 M
Net Profit-31.13 M Operating Profit-27.05 M Total Assets215.34 M Total Current Assets189.75 M
Total Current Liabilities42.53 M Total Debt233.48 M Total Liabilities277.16 M Total Revenue15.93 M
Technical Data
High 52 week22.98 Low 52 week2.45 Last close17.79 Last change2.3%
RSI37.69 Average true range0.81 Beta0.51 Volume2.65 M
Simple moving average 20 days-0.63% Simple moving average 50 days-5.2% Simple moving average 200 days16.52%
Performance Data
Performance Week2.77% Performance Month0.74% Performance Quart0.74% Performance Half15.67%
Performance Year455.94% Performance Year-to-date30.71% Volatility daily2.76% Volatility weekly6.17%
Volatility monthly12.65% Volatility yearly43.83% Relative Volume527.59% Average Volume7.26 M
New High New Low

News

2019-06-21 13:39:19 | Amarin’s John Thero Awarded NJ EY Entrepreneur of The Year® 2019 Award for Life Sciences

2019-06-19 20:11:34 | Hedge Funds Have Never Been This Bullish On Amarin Corporation plc AMRN

2019-06-18 07:00:00 | Amarin to Present at the 2019 BMO Prescription For Success Healthcare Conference

2019-06-17 22:26:39 | Amarin Stock Poised for Even More Gains

2019-06-07 07:12:35 | Amarin to Present Findings Regarding Challenges of Current Treatment Options in Reducing Cardiovascular Risks for Diabetes Patients, Even for Those With Controlled Cholesterol Levels, at Annual American Diabetes Association ADA Meeting

2019-06-04 14:10:11 | Amarin Corporation plc NASDAQ:AMRN: When Will It Breakeven?

2019-06-04 06:00:00 | Amarin to Present at the Goldman Sachs 40th Annual Global Healthcare Conference

2019-05-30 16:03:32 | 5 Top Stock Trades for Friday: AAPL, VEEV, DG, DLTR

2019-05-30 08:28:12 | Amarin Rises on Priority Review for Vascepa Label Expansion

2019-05-30 07:31:00 | 3 Top Mid-Cap Stocks to Buy Right Now

2019-05-30 07:00:00 | Pharmaceutical Industry Veteran Gwen Fisher Joins Amarin to Lead Corporate Communications

2019-05-29 23:44:21 | This Biotech Stock Rocketed Near A Buy Point On Speedy Drug Review

2019-05-29 16:32:00 | Why Cypress Semiconductor, Amarin, and Heico Jumped Today

2019-05-29 14:12:21 | Amarin shares soar after FDA agrees to fast-track review of its prescription strength fish oil pill for heart patients

2019-05-29 13:04:08 | Bulls shop at this discount retailer

2019-05-29 11:58:00 | Here's Why Amarin Soared Today

2019-05-29 10:37:41 | Amarin's Cardiovascular Fish Oil Pill May Hit Market Sooner: FDA Accords Priority Review Designation

2019-05-29 06:00:00 | U.S. FDA Grants Priority Review for Vascepa® Icosapent Ethyl Supplemental New Drug Application Seeking Cardiovascular Risk Reduction Indication

2019-05-24 13:20:06 | Options traders say it's hip to be Square

2019-05-23 07:31:00 | Label Expansion to Boost Revenue Growth for Amarin’s Vascepa

2019-05-22 11:10:02 | How Did Amarin’s Vascepa Perform in Fiscal 2019?

2019-05-22 09:40:02 | Comparing Revenue Growth Trends for AMRN and IOVA

2019-05-22 08:07:37 | What Are Analysts Recommending for AMRN and IOVA in May?

2019-05-16 16:15:00 | Vascepa® to Be Featured in Multiple Scientific Sessions at the National Lipid Association Annual Meeting

2019-05-06 10:16:01 | Why Did Amarin AMRN Stock Sink After Earnings? Analysts Explain

2019-05-02 14:18:14 | 5 Biotech Stocks With Near-Term Catalysts Ahead

2019-05-02 09:34:01 | Options Traders Expect Huge Moves in Amarin AMRN Stock

2019-05-02 08:33:00 | Why Amarin's Stock Sank on Strong First-Quarter Results

2019-05-01 15:00:00 | Here's What You Need to Know From Amarin's Q1 Earnings Update

2019-05-01 13:47:03 | Edited Transcript of AMRN earnings conference call or presentation 1-May-19 11:30am GMT

2019-05-01 11:54:49 | Amarin Corporation plc AMRN Q1 2019 Earnings Call Transcript

2019-05-01 08:53:12 | Amarin AMRN Beats Estimates for Earnings & Revenues in Q1

2019-05-01 05:10:34 | Amarin: 1Q Earnings Snapshot

2019-05-01 05:00:00 | Amarin Reports First Quarter 2019 Financial Results and Provides Update on Operations

2019-04-29 21:43:00 | 4 More Healthcare Earnings Reports to Watch This Week

2019-04-29 06:00:00 | New Drug Submission Filed for Vascepa® with Health Canada

2019-04-25 12:24:02 | What Kind Of Investor Owns Most Of Amarin Corporation plc NASDAQ:AMRN?

2019-04-24 13:32:56 | Were Hedge Funds Right About Flocking Into Amarin Corporation plc AMRN ?

2019-04-24 12:06:04 | What's in the Cards for Amarin AMRN This Earnings Season?

2019-04-24 06:00:00 | Amarin To Report First Quarter 2019 Results and Host Conference Call On May 1, 2019

2019-04-23 11:35:00 | CLASS ACTION DEADLINE for CAG and AMRN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2019-04-23 11:03:00 | DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Amarin Corporation plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-04-23 09:39:21 | CLASS ACTION UPDATE for AMRN, SYNH, WSR and FSNN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2019-04-22 21:55:00 | FINAL DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Amarin Corporation plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-04-22 15:55:00 | CLASS ACTION UPDATE for AMRN, NTNX and BA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2019-04-22 15:00:00 | FINAL DEADLINE ALERT - AKRX, HIIQ & AMRN - Bronstein, Gewirtz & Grossman, LLC

2019-04-22 13:20:00 | SHAREHOLDER ALERT: AMRN BPI NTNX: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

2019-04-22 11:17:43 | DEADLINE TUESDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Amarin Corporation plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-04-22 10:05:46 | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of AMRN, VNDA, WTW and APYX

2019-04-22 09:58:00 | FINAL DEADLINE - AKRX, HIIQ & AMRN - Bronstein, Gewirtz & Grossman, LLC